Enanta Pharmaceuticals Inc (ENTA)vsNovartis AG ADR (NVS)
ENTA
Enanta Pharmaceuticals Inc
$11.55
-5.17%
HEALTHCARE · Cap: $329.41M
NVS
Novartis AG ADR
$156.86
-0.50%
HEALTHCARE · Cap: $286.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 86775% more annual revenue ($56.69B vs $65.26M). NVS leads profitability with a 22.5% profit margin vs -96.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
ENTA
Avoid21
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.1%
Fair Value
$22.30
Current Price
$11.55
$10.75 discount
Margin of Safety
-67.2%
Fair Value
$93.84
Current Price
$156.86
$63.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -53.2% — below average capital efficiency
Revenue declined 21.6%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ENTA
ENTA has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : ENTA
The primary concerns for ENTA are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
ENTA profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
ENTA carries more volatility with a beta of 0.96 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 21/100), backed by strong 22.5% margins. ENTA offers better value entry with a 36.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enanta Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?